15500-66-0 Pancuronium bromide AKSci H857
 
 
Loading Please Wait...
  H857    AKSci Reference Standard
Pancuronium bromide
, 98% (HPLC)
 



IDENTITY
CAS Number:15500-66-0
MDL Number:MFCD00079223
MF:C35H60Br2N2O4
MW:732.67
EINECS:239-532-5
BRN:4226892
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:229-234°C
Optical Rotation:+38.6° (c=1% in H2O)
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply to certain package sizes and shipment methods. Please check pricing table for an indicator of applicable hazmat fees.

BIOLOGICAL INFO
Solubility:100mg/ml in H2O: clear light yellow solution
Application(s):Competitive acetylcholine antagonist
Form:Bromide
Research Area:Neurological disease

REVIEW

 Pancuronium (trademarked as Pavulon) is a steroid based muscle relaxant. It is the second of three drugs administered during most lethal injections in some parts of the the United States. Pancuronium is a typical non-depolarizing curare-mimetic muscle relaxant, acting as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine from its post-synaptic nicotinic acetylcholine receptors. Pancuronium is a very potent muscle relaxant/curaremimetic. The ED95 (i.e. dose causing 95% depression of muscle twitch response) is 60 µg/kg body weight administered intravenously. Muscle relaxation suitable for intubation sets in about 90-120 seconds after administration of the drug. Full muscle paralysis for major surgery is achieved about 2-4 minutes after application. Clinical effects (muscle activity lower than 25% of physiological) last for about 100 minutes. The time needed for full (over 90% muscle activity) recovery after single administration is about 120-180 minutes in healthy adults, but can be protracted to more hours in poor health subjects and when concomitantly administered with other long-acting anesthetics (e.g., some opioids, barbiturates, inhalation anesthetics). The effects of pancuronium can be at least partially reversed by anticholinesterasics, such as neostigmine, pyridostigmine, and edrophonium.

REFERENCES
[1]ourc'h, G.; Lecharny, B.; Madre, F. Pancuronium bromide, a new curarizing drug Anesthesie, Analgesie, Reanimation (1971), 28(1), 1-20.
[2] Black, G. W.; Clarke, R. S. J. Recently introduced anesthetic drugs International Anesthesiolog Clinics (1971), 9(3), 171-96.
[3] Speight TM, Avery GS. Pancuronium bromide: a review of its pharmacological properties and clinical application. Drugs. 1972;4(3):163-226.
[4] Roizen MF, Feeley TW. Pancuronium bromide. Ann Intern Med. 1978;88(1):64-8.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Danger

Hazard Statements
H301

Precautionary Statements
P264; P270; P301+P310; P321; P330; P405; P501


Current as of May 12, 2024

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

All products are stocked and shipped from San Francisco Bay Area, California, USA.

⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.

These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.

Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.



CATEGORIES

 APIs and Bioactives >


PubChem
  @PubMed